Good T Cells
Latest round
- Series B
Last raised
- Dec 2020
Total raised
- $35M
Investors
- 10
About Good T Cells
Based in Seoul, South Korea, and established in 2016, Good T Cells, Inc. is a biomedical company that developing immunotherapeutic and diagnostic reagents for cancer and autoimmune diseases. The company is developing immune cell therapy for solid tumors and autoimmune diseases. Candidate drugs, GTC110-04 treated for solid tumors, GTC12-01 treated for gastric cancer, and GTC10-01, GTC22-01, and GTC2330-01 treated for auto-immune diseased. The GTC10-01 and GTC110-04 have been entered into the pre-clinic trial phase, and other candidates' drugs have been in the discovery phase.
Who invested in Good T Cells
10 investors across 1 round
See all investors in Good T Cells
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Dec 22, 2020
Amount
$35M
Investors
Questions about Good T Cells
Who invested in Good T Cells?
Good T Cells has 10 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Good T Cells raised?
Good T Cells has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Good T Cells last raise money?
Good T Cells's most recent round on record is a Series B, in Dec 2020.
What does Good T Cells do?
Based in Seoul, South Korea, and established in 2016, Good T Cells, Inc.
Where is Good T Cells headquartered?
Good T Cells is headquartered in Seoul, South Korea.
Which VCs invest in companies like Good T Cells?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Good T Cells's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Good T Cells? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.